Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: J Am Coll Cardiol. 2009 Dec 1;54(23):2129–2138. doi: 10.1016/j.jacc.2009.09.009

Figure 4. Cumulative incidence of cardiovascular events in the JUPITER trial, according to study group.

Figure 4

Panel A shows the cumulative incidence of the primary endpoint (nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, hospitalization for unstable angina, or confirmed death from a cardiovascular cause). Panel B shows the cumulative incidence of nonfatal myocardial infarction, nonfatal stroke, or confirmed death from a cardiovascular cause. Panel C shows cumulative incidence for arterial revascularization or hospitalization for unstable angina. Panel D shows the cumulative incidence of death from any cause. [Adopted from Ridker PM, Danielson E, Fonseca FAH, Genest J, Gottto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.]